Myocardial infarction causes myocardium thinning, fibrosis, and progressive heart failure. Engineered human myocardium (EHM) is tested clinically as a first-in-class product for sustainable remuscularization in patients with advanced heart failure. Current EHM production procedure from iPSC-derived cardiomyocytes and stromal cells, is time consuming and involves thin constructs. Here, I introduce 4D-DLP-printed foldable scaffolds with potential to create modular cylindrical cardiac bricks. This enables self-assembly into thicker and aligned sarcomeres with synchronous contractility mimicking a native myocardium. When optimized and integrated with cryopreservation protocols, the biomanufacturing and biobanking of these cellular building blocks may overcome current EHM limitations and advance translational regenerative therapies for myocardial infarction. The structure-material properties investigations into these new class of life building blocks paves the way for future medical breakthroughs.